Company intelligence / Profile preview

Guangzhou Huibairui Biomedical Technology Co., Ltd.

Guangzhou, Guangdong Province, Chinainewsource.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Guangzhou Bairui Biomedical Technology Co., Ltd. (also referred to as Huibairui) develops cell therapies for cancer, with its lead program BGT007 and a variant BGT007H currently in early phase clinical trials targeting recurrent or metastatic refractory digestive tract tumors. The company has at least two ongoing investigator-sponsored early phase clinical studies evaluating safety and initial efficacy of these cell therapies.

Therapeutic areas: Oncology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

1 asset

KDR2-2

Beyond the preview

Go deeper on Guangzhou Huibairui Biomedical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Huibairui Biomedical Technology Co., Ltd..

Explore the full profile